Oral Oncology Reports最新文献

The use of international radiotherapy consensus guidelines for primary clinical target volume delineation for oropharyngeal carcinoma: case series with recurrence pattern analysis 使用国际放射治疗共识指南划定口咽癌的主要临床靶体积：病例系列与复发模式分析

Oral Oncology Reports Pub Date : 2025-09-19 DOI: 10.1016/j.oor.2025.100765

Alina Kiewell , Lily Bevan , Chinyereugo Umemneku-Chikere , Robin.J.D. Prestwich , Zsuzsanna Iyizoba Ebozue

{"title":"The use of international radiotherapy consensus guidelines for primary clinical target volume delineation for oropharyngeal carcinoma: case series with recurrence pattern analysis","authors":"Alina Kiewell , Lily Bevan , Chinyereugo Umemneku-Chikere , Robin.J.D. Prestwich , Zsuzsanna Iyizoba Ebozue","doi":"10.1016/j.oor.2025.100765","DOIUrl":"10.1016/j.oor.2025.100765","url":null,"abstract":"<div><h3>Background</h3><div>International consensus guidelines for head and neck cancer primary clinical target volume (CTV) delineation based upon a geometric ‘5 + 5’ expansion and anatomical editing were published in 2018. Analysis of recurrence patterns in relation to target volumes is required to validate this approach.</div></div><div><h3>Methods</h3><div>Patients with oropharyngeal carcinoma treated between 2019–22 with definitive (chemo)radiotherapy using the guideline approach to primary CTV delineation were identified. Patterns of locoregional recurrence were analysed using combined spatial and dosimetric analysis. Central, high dose recurrences were defined by mapped a centroid of the volume of recurrence (Vrec) to within the high dose planning target volume (PTV) and >95 % of Vrec receiving >95 % of prescribed dose to high dose PTV.</div></div><div><h3>Results</h3><div>133 patients were treated using the consensus outlining guidelines. Median follow up was 3.9 years. 78.9 % had p16 positive disease. 3-year local and regional control rates were 96 % and 94.7 %. Locoregional recurrence occurred in 6/133 (4.5 %) of patients including 3 patients with primary site recurrences. All primary site recurrences were classified as central high dose recurrences.</div></div><div><h3>Conclusions</h3><div>All primary tumour site recurrences were within the high dose volume with no evidence of marginal or out-of-field recurrences. There results provide evidence for the safety of the consensus outlining approach for primary tumour CTVs.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"16 ","pages":"Article 100765"},"PeriodicalIF":0.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145121083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Photodynamic therapy for cancer” [Oral Oncol Rep 9 (2024) 100129] “癌症光动力疗法”的勘误表[Oral Oncol Rep 9 (2024) 100129]

Oral Oncology Reports Pub Date : 2025-09-01 DOI: 10.1016/j.oor.2025.100742

Shrikant B. Mali, Sachinkumar Dahivelkar

引用次数: 0

Corrigendum to “Delta Radiomics — Potential role in Head Neck Cancer” [Oral Oncol Rep 12 (2024) 100676] “Delta放射组学-头颈癌的潜在作用”的勘误表[Oral Oncol Rep 12 (2024) 100676]

Oral Oncology Reports Pub Date : 2025-09-01 DOI: 10.1016/j.oor.2025.100745

Shrikant Balasaheb Mali

引用次数: 0

Corrigendum to “Role of Cold atmospheric plasma in cancer management” [Oral Oncol Rep 9 (2024) 100133] “低温大气血浆在癌症治疗中的作用”的勘误表[Oral Oncol Rep 9 (2024) 100133]

Oral Oncology Reports Pub Date : 2025-09-01 DOI: 10.1016/j.oor.2025.100751

Shrikant Balasaheb Mali

引用次数: 0

Corrigendum to “Social media in health care - Ethically challenging - Dangerous but attractive- -use with caution” [Oral Oncol Rep 7 (2023) 100079] “医疗保健中的社交媒体-伦理挑战-危险但有吸引力-谨慎使用”的勘误表[Oral Oncol Rep 7 (2023) 100079]

Oral Oncology Reports Pub Date : 2025-09-01 DOI: 10.1016/j.oor.2025.100753

Shrikant Balasaheb Mali

引用次数: 0

Corrigendum to “End of life and palliative care decisions in advanced head neck cancer” [Oral Oncol Rep 11 (2024) 100569] “晚期头颈癌的生命终结和姑息治疗决策”的勘误表[Oral Oncol Rep 11 (2024) 100569]

Oral Oncology Reports Pub Date : 2025-09-01 DOI: 10.1016/j.oor.2025.100744

Shrikant Balasaheb Mali

引用次数: 0

Corrigendum to “Nanotechnology in photodynamic therapy” [Oral Oncology Reports 10 (2024) 100307] “光动力治疗中的纳米技术”的勘误表[口腔肿瘤学报告10 (2024)100307]

Oral Oncology Reports Pub Date : 2025-09-01 DOI: 10.1016/j.oor.2025.100750

Shrikant B. Mali, Sachinkumar Dattatray Dahivelkar

引用次数: 0

Corrigendum to “Panoptosis – new frontier in research in head neck cancer” [Oral Oncol Rep 10 (2024) 100310] “Panoptosis -头颈癌研究的新前沿”的勘误表[Oral Oncol Rep 10 (2024) 100310]

Oral Oncology Reports Pub Date : 2025-09-01 DOI: 10.1016/j.oor.2025.100752

Shrikant Balasaheb Mali

引用次数: 0

Corrigendum to “RNA-binding protein HuR reprograms immune T cells and promotes oral squamous cell carcinoma” [Oral Oncol Rep 10 (2024) 100296] “rna结合蛋白HuR重编程免疫T细胞并促进口腔鳞状细胞癌”的勘误表[oral Oncol Rep 10 (2024) 100296]

Oral Oncology Reports Pub Date : 2025-09-01 DOI: 10.1016/j.oor.2025.100740

Mrinmoyee Majumder , Harinarayanan Janakiraman , Paramita Chakraborty , Anitha Vijayakumar , Sari Mayhue , Hong Yu , Toros Dincman , Romeo Martin , Elizabeth O'Quinn , Shikhar Mehrotra , Viswanathan Palanisamy

引用次数: 0

Corrigendum to “Mini review of spatially fractionated radiation therapy for cancer management” [Oral Oncol Rep 9 (2024) 100175] “空间分割放射治疗用于癌症管理的综述”的勘误表[Oral Oncol Rep 9 (2024) 100175]

Oral Oncology Reports Pub Date : 2025-09-01 DOI: 10.1016/j.oor.2025.100741

Shrikant Balasaheb Mali

引用次数: 0